Get this delivered to your inbox, and more info about our products and services.
This biotech made it through a 'time correction.' The charts say it could be time to buy
David Keller breaks down the charts on Incyte Corp.
14 words~1 min read
Related reading
The charts are showing this biotech stock can strengthen into year-end
David Keller breaks down the technicals on this biotech giant.
This biotech stock could see a sharp swing higher after years of struggling,…
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
There's a 'bearish-to-bullish' reversal happening in this biotech stock, says…
Carter Worth breaks down the charts on this biotech stock.
There's a 'bearish-to-bullish' reversal happening in this mid-cap biotech…
Carter Worth takes a look at the charts for mid-cap biotech Immunovant.
A bullish breakout in this little-known pharma stock is forming, charts show
Frank Cappelleri of CappThesis breaks down the bullish technical backdrop for this pharma-related stock.
A catalyst-rich biotech may be poised to resume its recovery. Use options to…
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.